Since we demonstrated that LDHC silencing increases DNA damage accumulation in breast cancer cells with alterations in the expression of DNA damage sensors upstream of the DDR pathway, we explored the sensitivity of shLDHC cells to olaparib and cisplatin. Here, LDHC is linked to breast carcinoma.